CAJ | 학술논문

目的观察尿激酶原(Pro-uk)溶栓治疗急性心肌梗死(AMI)的疗效及安全性.方法随机选择2004.05-2005.05间于内蒙古医学院第一附属医院住院的68例发病6 h内的AMI患者,分为Pro-uk组(n=43)和尿激酶(UK)组(n=25).其中Pro-uk 50 mg组22例、Pro-uk 60 mg组21例.在溶栓90 min时进行选择性冠状动脉造影,评价梗死相关动脉开通情况,评价早期心脏事件发生率、出血并发症以及不良反应发生率.结果 ①Pm-uk组总的梗死相关动脉再通率(TIMl2级+TIMl3级)为76.7%,明显高于UK组52.2%(P=0.041).②Pro-uk组轻度出血并发症显著低于UK组(P=0.029);两组均无颅内出血等严重并发症发生.③早期心脏事件发生率以及不良反应发生率两组差异均无统汁学意义.结论 Pro-uk静脉溶栓治疗AMI安全有效.
목적 관찰뇨격매원(Pro-uk)용전치료급성심기경사(AMI)적료효급안전성.방법 수궤선택2004.05-2005.05간우내몽고의학원제일부속의원주원적68례발병6 h내적AMI환자,분위Pro-uk조(n=43)화뇨격매(UK)조(n=25).기중Pro-uk 50 mg조22례、Pro-uk 60 mg조21례.재용전90 min시진행선택성관상동맥조영,평개경사상관동맥개통정황,평개조기심장사건발생솔、출혈병발증이급불량반응발생솔.결과 ①Pm-uk조총적경사상관동맥재통솔(TIMl2급+TIMl3급)위76.7%,명현고우UK조52.2%(P=0.041).②Pro-uk조경도출혈병발증현저저우UK조(P=0.029);량조균무로내출혈등엄중병발증발생.③조기심장사건발생솔이급불량반응발생솔량조차이균무통즙학의의.결론 Pro-uk정맥용전치료AMI안전유효.
Objective To investigate the therapeutic effect and side effect of prourokinase (Pro-uk) on the patients with acute myocardial infarction. Method From May 2004 to May 2005, a total of 68 cases of acute myocardial infarction treated by thrombolytic agents within 6 hours after onset were divided randomly into Pro-uk group ( n = 43) and urokinase (UK) group ( re = 25). In the Pro- uk group, there were 22 eases treated with 50 mg Pro-uk and 21 cases prescribed in 60 mg Pro-uk. The patency of involved coronary artery was evaluated by using selective coronary angiography at 90 minutes after thrombolytic therapy. The incidence of early heart events, bleeding and adverse reaction, were alse observed. Results (1) The total rates of resumed patency of obstructed coronary artery (TIMI grade 2 and 3 flow) were 76.7% in Pro-uk treated patients and 52.2% in UK treated patient ( P = 0. 041). (2) The occurrence of hyporrhea was lowered more significantly in Pro-uk treated patients than in UK treated patients (P = 0.029), but there were no intracranial hemorrhage found in both group. (3) Early cardiac events and adverse reactions were similar between two groups. Conclusions Pro-UK is safe and effective for the patients with acute myocardial infarction.